Home / Genomic Tests / Liquid Trace® Hematology
LIQUID TRACE / cfDNA + cfRNA

Liquid Trace®
Hematology

cfDNA + cfRNA Liquid Biopsy for Blood Cancers

Understand the disease that remains.

Integrate circulating genomic, RNA and clonality insights for a broader molecular view of hematologic disease.

A woman with eyes gently closed, surrounded by conceptual blood cells, jade DNA and orange RNA strands.
Conceptual image
The essentials

Testing at a Glance

cfDNAGenomic alterations
cfRNAGene-message information
10 mLEDTA blood specimen
IntegratedMolecular interpretation

Explore Hematologic Conditions

Multiple Myeloma — Explore testing in the context of the diagnosis, prior results and the clinical question.

View the Myeloma Page ↗
Complementary molecular insights

Why Evaluate Both cfDNA and cfRNA?

In hematologic disease, an integrated molecular profile can bring together circulating genomic findings, RNA expression and clonality information. These complementary perspectives support a broader assessment than an isolated mutation or clonotype alone.

cfDNA

Cell-free DNA consists of DNA fragments outside intact cells. Tumor-associated alterations in those fragments can provide genomic information.

  • Sequence alterations
  • Copy number and chromosomal findings
  • Genomic context for interpretation

cfRNA

Cell-free RNA adds information about gene messages. It can contribute evidence about expressed fusions, gene expression and abnormal splicing.

  • Expressed gene fusions
  • Expression patterns
  • Splice-related information

Different Signals. An Integrated Interpretation.

RNA abundance and molecular shedding vary. The value of the combined profile comes from evaluating complementary findings together—not from assuming every sample contains every signal.

For clinicians

Insights That Support Clinical Decisions

Review molecular evidence in the context of diagnosis, treatment history and the complete clinical workup.

Conceptual molecular illustration
01 / UNDERSTAND

Disease Characterization

Integrate mutations, chromosomal findings and RNA information with the clinical and pathology evaluation.

Conceptual molecular illustration
02 / EVALUATE

Clonality & Monitoring

Consider B- and T-cell clonality alongside other disease-associated findings when evaluating serial samples.

Conceptual molecular illustration
03 / INTEGRATE

Treatment Context

Review relevant molecular biomarkers and CAR-T construct findings in the context of the patient’s therapy.

Conceptual scientific illustrations.

Look Beyond Clonality

A clonality finding is one part of the disease profile. Mutations, fusions, expression and chromosomal findings provide additional information for integrated interpretation.

Interpret Serial Findings Carefully

Compare results alongside treatment history, marrow findings, blood counts and other relevant studies. Clinical interpretation matters when a molecular signal persists or changes.

Add CAR-T Construct Information

GTC’s current resources include CAR-T reporting. Construct detection adds a molecular observation; it does not by itself establish that the cells remain functional or that treatment is effective.

Use the Right Sampling Approach

Peripheral blood and bone marrow answer different questions. Liquid biopsy may contribute useful information, while marrow or tissue evaluation can remain necessary for diagnosis and management.

The molecular story

Beyond Clonality.

cfDNA + cfRNA

Beyond the Clonotype.

Combine a clonality finding with broader molecular context.

Conceptual molecular storytelling illustration

Select a scene to explore the story. These are conceptual visuals, not patient results.

VAF and Tumor Load Answer Different Questions

MeasureWhat it describesHow to read it
Variant allele frequency (VAF)The fraction of assessed DNA molecules carrying a particular variant.A relative molecular measure. Interpret it alongside sample composition and the variant’s clinical context.
Tumor loadA quantitative molecular signal, reported as mutant molecules per unit volume when applicable.A concentration-based measure for comparison in an appropriate longitudinal setting, rather than a direct measurement of tumor size.

Confirm the quantitative metrics applicable to the specimen and report with GTC.

For patients & families

Understanding Your Liquid Biopsy

Your doctor may use cell-free DNA and RNA in a blood sample to add information about a blood cancer. Results are interpreted with your other laboratory and clinical findings.

Will I still need a bone marrow biopsy?

Possibly. Liquid biopsy and bone marrow testing answer different questions. Your doctor will explain which tests are needed.

Will this identify a treatment?

The test may inform treatment discussions, but a treatment match is not guaranteed. Your doctor will explain what the findings mean for you.

What if the result is negative?

A negative result does not rule out cancer. Your care team will consider other test results and whether further evaluation is needed.

Testing is ordered through your treating clinician. Discuss suitability and collection with your care team.

Getting started

Sample Requirements & Ordering

A clear path from selecting the test to submitting the specimen.

Select Testing

Choose Liquid Trace® Hematology and complete the requisition.

Collect the Sample

The clinical team selects and collects an appropriate specimen.

Submit the Specimen

Include relevant clinical information and follow GTC’s shipping instructions.

Peripheral blood

10 mL EDTA Blood

Submit 10 mL peripheral blood in an EDTA tube. Coordinate collection, labeling, packaging and prompt shipment with the submitting team and GTC.

Protect the RNA information. GTC lists RNA stability as 48–72 hours from blood draw. Samples received beyond 72 hours may yield DNA-only results. Coordinate collection and prompt shipment with the laboratory.

Ready to Arrange Testing?

Get collection instructions and help choosing the right test.

Your questions, answered

Frequently Asked Questions

How does this differ from DNA-only liquid biopsy?

Liquid Trace evaluates cfDNA and cfRNA. RNA contributes gene-message information that complements the genomic findings from DNA.

Does this replace other diagnostic tests?

No single test answers every clinical question. The treating team may use liquid biopsy with tissue pathology, imaging and other studies.

How long do results take?

Contact GTC to confirm the current turnaround time for the selected assay, specimen and clinical circumstances.

How do I order testing?

Use GTC’s ordering resources or call 866-484-8870. Patients should work with their treating clinician.

Turn Molecular Insight Into a More Informed Conversation

Discuss the right specimen and test for the clinical question.

Contact GTC ↗